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Aneuploidy is a hallmark of most human cancers, but whether it is a cause or a consequence of 
cellular transformation remains a subject of debate. The spindle checkpoint functions to prevent 
aneuploidy and plays a central role in this discussion. The checkpoint gene Mad2 is activated by 
E2F and overexpressed in cells lacking a functional Rb pathway. In this issue of Cancer Cell, Sotillo 
and coworkers report that Mad2 overexpression leads to chromosomal instability and tumorigen-
esis, indicating that Mad2 contributes to cancer development after Rb mutation. In a second paper, 
Weaver et al. report that aneuploidy has both tumor-promoting and -suppressing properties.Aneuploidy, a state of having an 
abnormal number of chromosomes, 
is a hallmark of most human tumors 
(Weaver and Cleveland, 2005). Aneu-
ploidy results from missegregation of 
chromosomes during mitosis, but its 
molecular basis and role in the causa-
tion of human cancer remain largely 
unclear. The spindle checkpoint is 
an intricate multiprotein network that 
delays the onset of anaphase until all 
kinetochores are properly attached to 
the mitotic spindle and aligned in the 
metaphase plate. Since the discovery 
of this checkpoint, there has been 
much speculation that its malfunction 
plays a major role in the development 
of aneuploidy and cancer. Genes 
encoding key components of the 
spindle checkpoint are rarely mutated 
in human cancers, but some of these 
genes are quite often expressed at 
reduced or elevated levels. Mouse 
models mimicking these reductions 
have moderate to severe aneuploidy, 
and some of these develop carcino-
gen-induced tumors at increased 
rates, implying that at least certain 
mitotic checkpoint genes act to sup-
press malignant cell transformation 
(Baker et al., 2005).
Mad2 expression must be tightly 
regulated because both reduced 
amounts and overproduction of the 
protein induce aneuploidy (Dobles 
et al., 2000; Hernando et al., 2004; 
Michel et al., 2001) (Figure 1). How-
ever, whether Mad2 overexpres-
sion acts to drive tumorigenesis has 
remained an open question. A study by Sotillo et al. in this issue of Can-
cer Cell now addresses this issue 
(Sotillo et al., 2007). The authors cre-
ated transgenic mice in which the 
overexpression of Mad2 can either 
be induced or repressed by doxycy-
cline. Mice in which the transgene 
was constitutively “on” developed a 
wide variety of tumors, including liver 
and lung carcinomas, sarcomas, and 
lymphomas. Most of these tumors 
emerged in the second year of life 
and continued to grow even when 
the Mad2 transgene was switched 
Figure 1. Mitotic Checkpoint Genes and Tumorigenesis
Mad2 is an E2F-regulated gene whose level of expression must to be tightly controlled during 
the cell cycle to maintain euploidy. In human cancer cells lacking a functional RB pathway, E2F 
is hyperactive, resulting in overexpression of Mad2, which, in turn, leads to aneuploidy, tetra-
ploidization, and structural chromosomal damage, and formation of aggressive tumors in a broad 
spectrum of tissues and cell types. On the other hand, aneuploidy resulting from downregulation 
of Mad2 expression is linked to formation of nonaggressive lung tumors with long latency and 
low incidence. Because Mad2 presumably has functions outside the spindle checkpoint, it is not 
entirely sure that aneuploidy drives tumorigenesis in Mad2 haploinsufficient mice. In contrast, the 
expression and function of CENP-E seems to be restricted to mitosis. Aneuploidy arising from 
CENP-E haploinsufficiency causes a mild cancer phenotype in lymphocytes and lung epithelium, 
but not in other tissues and cell types. Surprisingly, in the presence of certain cancer-critical gene 
mutations, aneuploidy from CENP-E deficiency reduces tumor formation. Cancer Cell 11, January 2007 ©2007 Elsevier Inc. 
Cancer Cell
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of Mad2 are not required for tumor 
maintenance. Together, these ele-
gant experiments firmly establish that 
Mad2 has oncogenic properties and 
imply that hyperactivation of Mad2 by 
E2F1 drives neoplastic transforma-
tion of cells in which the Rb pathway 
is disrupted.
Mice overexpressing Mad2 undergo 
frequent chromosome missegrega-
tion and accumulate aneuploid cells, 
as do mice with low amounts of Mad2 
(Michel et al., 2001; Sotillo et al., 2007) 
(Figure 1). However, compared to mice 
with low Mad2 levels, mice with high 
levels of the protein have a much wider 
tumor spectrum than Mad2-haplo-
insufficient mice. In addition, tumors 
from Mad2 transgenic mice appear to 
be much more aggressive than those 
from Mad2-haploinsufficient mice. 
What might be the basis for these 
profound differences in tumorigenic 
properties? Besides aneuploidy, Mad2 
transgenic mice also develop several 
structural chromosome defects such 
as chromosome breaks, end-to-end 
fusions, interstitial deletions, and 
chromosomal amplifications. Struc-
tural abnormalities or structural and 
numerical abnormalities combined 
might pose a much higher risk for neo-
plastic transformation than aneuploidy 
alone, perhaps explaining why Mad2 
overexpression is more tumorigenic 
than Mad2 insufficiency. How struc-
tural chromosomal abnormalities arise 
in cells with high levels of Mad2 is cur-
rently unclear. Mad2 overexpression 
results in the incomplete destruction 
of cyclin B and securin in late meta-
phase, which, in turn, is likely to impair 
the activation of separase (Hernando 
et al., 2004; Sotillo et al., 2007). One 
possible scenario would therefore be 
that cells with high levels of Mad2 are 
driven into anaphase when cohesins 
that hold sister chromatids together 
are still incompletely cleaved, thereby 
promoting mechanical breakage of 
unresolved sister chromatids as they 
move toward opposite poles of the 
spindle. Another characteristic of cells 
that overexpress Mad2, not seen in 
cells with low amounts of the protein, is 
failure of cytokinesis, which results in 
tetraploidization. In p53 null cells, tet-
raploidy has been shown to accelerate 2 Cancer Cell 11, January 2007 ©2007 Enumerical and structural chromosome 
instability and promote tumorigen-
esis (Fujiwara et al., 2005). Thus, an 
increase in structural rearrangements 
and tetraploidization may, at least in 
part, explain why Mad2-overexpress-
ing mice are so much more suscep-
tible to spontaneous tumors than 
Mad2-haploinsufficient mice.
With the causal involvement of 
Mad2 overexpression in tumorigene-
sis firmly established, it will be impor-
tant to determine whether other mitotic 
checkpoint proteins also cause chro-
mosomal instability and cancer when 
expressed at supranormal levels. An 
obvious protein to test would be the 
Mad2-interacting protein BubR1. Like 
Mad2, BubR1 is important for proper 
timing of cyclin B degradation at the 
metaphase-to-anaphase transition, 
and therefore its overexpression 
may also lead to incomplete activa-
tion of separase, and as a result, to 
numerical and structural chromo-
some abnormalities, and tetraploidi-
zation. On the other hand, BubR1 
has also been implicated in induc-
tion of apoptosis following chromo-
some missegregation. It is possible 
that this function may be reinforced 
by BubR1 overexpression and per-
haps act to prevent tumorigenesis. 
Notably, mitotic checkpoint genes 
including BubR1 are frequently over-
expressed in human cancers (Weaver 
and Cleveland, 2006). Despite this, 
these studies are likely to provide 
underestimated rates because there 
may only be a transient need for 
mitotic checkpoint gene overexpres-
sion, as has been demonstrated for 
Mad2 by Sotillo et al. (2007).
Given that Mad2 transgenics 
develop structural chromosomal 
aberrancies in addition to aneu-
ploidy, one could argue that this 
mouse model is unsuitable for testing 
the 100-year-old hypothesis of The-
odor Boveri that aneuploidy drives 
tumorigenesis (Boveri, 1902). Oth-
ers have previously attempted to test 
Boveri’s hypothesis by using mice 
with reduced amounts of the check-
point proteins Mad2, BubR1, or Rae1 
(a Bub3-related checkpoint protein) 
(Baker et al., 2005). These mouse 
models accumulate aneuploid cells, 
and BubR1 and Rae1 are prone to lsevier Inc.carcinogen-induced tumors. How-
ever, since Mad2, BubR1, and Rae1 
are expressed throughout the cell 
cycle and implicated in cellular pro-
cesses other than mitotic checkpoint 
control, such as apoptosis, DNA 
replication, and nucleocytoplasmic 
transport, one could argue that these 
models are also not ideal for testing 
the Boveri hypothesis. CENP-E is 
a mitotic checkpoint protein whose 
expression and function seem to be 
narrowly restricted to mitosis. In this 
issue of Cancer Cell, Weaver and col-
leagues show that mice with reduced 
CENP-E levels develop aneuploidy 
and late-life splenic lymphomas and 
lung tumors, thereby providing the 
most compelling evidence yet that 
numerical chromosomal instability 
plays a causal role in tumorigenesis, 
at least in a subset of tissues (Weaver 
et al., 2007) (Figure 1). The authors 
further show that CENP-E mutant 
mice are protected against tumors 
caused by the DMBA carcinogen or 
by loss of the p19/ARF tumor sup-
pressor. These are surprising findings 
because aneuploidy was expected to 
promote but not inhibit tumorigen-
esis. There is currently no straight-
forward explanation for these results, 
but Weaver et al. have proposed that 
DMBA and loss of p19/ARF cause 
moderate levels of DNA damage 
and/or chromosome missegregation 
that, when combined with aneuploidy 
caused by reduction in CENP-E, drive 
rates of genetic instability above a 
threshold that is compatible with 
cell viability. In any case, the work of 
Weaver et al. shows that aneuploidy 
can exert tumor-suppressive, tumor-
promoting, or benign effects depend-
ing on tissue or cell type and the rep-
ertoire of additional cancer-critical 
gene mutations present in the cell. 
These findings stress the importance 
of identifying the genetic alterations 
that cooperate with mitotic check-
point gene mutations in the develop-
ment of cancer. It will also be critical 
to identify cancer gene mutations 
that negatively synergize with mitotic 
checkpoint defects or aneuploidy, as 
such efforts may contribute to the 
development of novel therapies for 
the treatment of a broad spectrum of 
human cancers.
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viewed as a homogeneous mass 
of rapidly proliferating cells, and 
therapeutics were designed to 
eliminate highly proliferative cells. 
But recent studies have suggested 
that tumor cells are heterogeneous 
with respect to proliferation and dif-
ferentiation, and that a cell’s prolif-
erative rate may be a poor indicator 
of its tumorigenic potential. In sev-
eral malignancies, the capacity to 
initiate and maintain tumor growth 
has been found to reside in a small 
population of cells called cancer 
stem cells (CSCs) (Al-Hajj et al., 
2004; Reya et al., 2001; Wicha et al., 
2006). Like normal stem cells, CSCs 
have the ability to self-renew and to 
give rise to the variety of prolifer-
ating and differentiated cells that 
make up the bulk of a tumor. Impor-
tantly, CSCs are often relatively 
quiescent and therefore may not be 
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The resistance of CSCs to conven-
tional therapies may help explain why 
such therapies often fail: although they 
may destroy the bulk of a tumor, they 
cannot prevent the surviving CSCs 
from kicking into action and regener-
ating it again (Al-Hajj et al., 2004; Reya 
et al., 2001; Wicha et al., 2006). In this 
view, effective cancer treatment will 
require targeting CSCs themselves. 
But what are the signals that regulate 
CSC survival and function, and is there 
an effective way to subvert them?
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with normal stem cells. An impor-
tant characteristic of normal neural 
stem cells (NSCs) is that they are 
concentrated in regions that are 
rich in blood vessels, called “vas-
cular niches” (Ramirez-Castillejo et 
al., 2006; Shen et al., 2004). These 
niches are thought to shelter NSCs 
from apoptotic stimuli and allow 
them to maintain a proper balance 
between self-renewal and differenti-
ation. Endothelial cells (ECs), which 
line blood vessels, secrete factors 
that promote stem cell survival and 
self-renewal and are thought to be a 
key component of the NSC niche.
A study in this issue of Cancer Cell 
suggests that CSCs in brain tumors, 
similar to NSCs, reside in vascular 
niches, and that disrupting these 
niches may be the key to eliminating 
CSCs (Calabrese et al., 2007). By 
analyzing a large cohort of human 
brain tumors, Calabrese et al. dem-
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